NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.5 EUR | -0.22% |
|
+0.99% | +43.70% |
| 06-28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| 06-28 | NOVO NORDISK : UBS gives a Neutral rating | ZD |
| Sales 2024 * | 292B 42.03B 39.06B 57.43B | Sales 2025 * | 352B 50.79B 47.2B 69.4B | Capitalization | 4,460B 643B 597B 878B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.04B 13.97B 20.54B | Net income 2025 * | 128B 18.44B 17.14B 25.2B | EV / Sales 2024 * | 15.4 x |
| Net Debt 2024 * | 22.58B 3.25B 3.02B 4.45B | Net cash position 2025 * | 5.93B 855M 794M 1.17B | EV / Sales 2025 * | 12.6 x |
| P/E ratio 2024 * |
43.3
x | P/E ratio 2025 * |
35.2
x | Employees | 66,015 |
| Yield 2024 * |
1.17% | Yield 2025 * |
1.44% | Free-Float | 70.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | -0.22% | ||
| 1 week | +0.99% | ||
| 1 month | +7.62% | ||
| 3 months | +12.08% | ||
| 6 months | +43.70% | ||
| Current year | +43.70% |
1 week
132.06
140.00
1 month
122.58140.00
Current year
92.60140.00
1 year
67.85140.00
3 years
35.44140.00
5 years
21.00140.00
10 years
14.70140.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 15-03-18 |
Helge Lund
CHM | Chairman | 62 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-28 | 134.5 | -0.22% | 8,835 |
| 24-06-27 | 134.8 | -0.03% | 4,129 |
| 24-06-26 | 134.8 | -1.99% | 5,429 |
| 24-06-25 | 137.6 | +3.91% | 5,437 |
| 24-06-24 | 132.4 | -0.59% | 2,765 |
Delayed Quote Deutsche Boerse AG, June 28, 2024 at 12:18 pm
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 815B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +2.04% | 224B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B |
- Stock Market
- Equities
- NOVO B Stock
- NOV Stock
